CanSino Biologics Inc. (HKG: 6185)
18.52
-0.06 (-0.32%)
Sep 9, 2024, 2:56 PM HKT
CanSino Biologics Employees
CanSino Biologics had 1,494 employees as of December 31, 2023. The number of employees decreased by 797 or -34.79% compared to the previous year.
Employees
1,494
Change (1Y)
-797
Growth (1Y)
-34.79%
Revenue / Employee
269.01K HKD
Profits / Employee
-1.10M HKD
Market Cap
7.52B
Employees Chart
CanSino Biologics News
- 1 year ago - Riding Covid Vaccine Highs, CanSino Plans Swiss Listing - Seeking Alpha
- 1 year ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 2 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 2 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 2 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 2 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 2 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire
- 2 years ago - Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant - PRNewsWire